HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crews, K. R. Search for Related Content PubMed PubMed Citation Articles by Crews, K. R.

KRISTINE R. CREWS, PHARM.D., BCPS, is Translational Research Laboratory Director, St. Jude Children’s Research Hospital, 332 N. Lauderdale, Mail Stop 313, Memphis, TN 38105 (Kristine.crews{at}stjude.org).

Purpose. Patient-specific factors that enter into decisions about the chemotherapy used to treat colorectal cancer are illustrated in several case studies. Summary. Genetic polymorphisms in genes that encode drug-metabolizing enzymes may affect the disposition and the risk for toxicity from chemotherapy agents used to treat colorectal cancer. Severe toxicity from 5-fluorouracil has been attributed to a deficiency in dihydropyrimidine dehydrogenase (DPD), but currently there is no widely used genetic test for DPD deficiency. An assay is available for genotypic testing of the enzyme UGT1A1, which is predictive of toxicity from irinotecan. Advanced age, prior pelvic or abdominal radiotherapy, a poor performance status, and increased pretreatment total bilirubin concentration also are associated with irinotecan-related toxicity. A reduction in irinotecan dosage or use of an alternative agent may be warranted in patients with risk factors for toxicity. Positive epidermal growth factor receptor (EGFR) expression by immunohistochemical (IHC) staining does not necessarily predict the response to cetuximab, a monoclonal antibody that binds EGFR, possibly because of the low sensitivity of the test. Carcinoembryonic antigen (CEA) is the tumor marker of choice for monitoring for progression of colorectal cancer. Conclusion. Individualizing chemotherapy based on disease stage, pharmacogenetics, prior therapy, patient age, performance status, and CEA level may help to optimize outcomes from chemotherapy for patients with colorectal cancer. Index terms: Age; Antineoplastic agents; Cetuximab; Colorectal neoplasms; Dosage; Drugs; Drugs, body distribution; Fluorouracil; Irinotecan; Metabolism; Pharmacogenetics; Polymorphism; Tests, laboratory; Toxicity

 

This article has been cited by other articles:

				H. Burris III and C. Rocha-Lima New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways Oncologist, March 1, 2008; 13(3): 289 - 298. [Abstract] [Full Text] [PDF]

				G. Richardson and R. Dobish Chemotherapy induced diarrhea Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 181 - 198. [Abstract] [PDF]